• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CASI CLINICI – Case Reports

Volume:

Biochimica Clinica 2021; 45(3) e020-e022

Pubblicato on-line:

Maggio 5, 2021

DOI:

10.19186/BC_2021.025

Scarica in PDF:

Neuromielite ottica in età pediatrica: il laboratorio può essere utile?
Case report: laboratory follow up of myelin oligodendrocyte glycoprotein antibodies titre associated to neuromyelitis optica spectrum disorder

AUTORI

Giulia Musso1, Margherita Nosadini2,3, Nicoletta Gallo1, Stefano Sartori2,3, Mara Seguso1, Mario Plebani1,4
1UOC Medicina di Laboratorio, Didas Servizi di Diagnostica Integrata, Azienda Ospedale – Università di Padova
2Neurologia e Neurofisiologia Pediatrica, Didas Salute della Donna e del Bambino, Azienda Ospedale – Università di Padova
3Gruppo di Neuroimmunologia, Istituto di Ricerca Pediatrica-Fondazione "Città della Speranza", Padova
4Dipartimento di Medicina - DIMED, Università di Padova

Questo lavoro è stato in parte presentato al 52° Congresso Nazionale SIBioC, 6-8 Ottobre 2020, Virtual Edition, nella Sessione Casi Cinici

ABSTRACT

Case report: laboratory follow up of myelin oligodendrocyte glycoprotein antibodies titre associated to neuromyelitis optica spectrum disorder

In September 2018 a previously healthy 6-years-old female was admitted for unspecific visual impairment. Physical examination revealed bilateral papilledema with haemorrhage signs, torpid photomotor reflex and slow eye-blink reflex. No other physical abnormalities or alterations in routine laboratory workup were found.
Brain imaging showed alterations in cortical white matter; both optic nerves and cervical spinal cordanti aquaporin-4 antibodies (AQP4-Ab) and myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) testing was then ordered suspecting a neuromyelitis optica spectrum disorder (NMOSD).
MOG-Ab positivity was found at >1:160 and at 1:40 titre in serum and in cerebrospinal fluid respectively. After steroid treatment, the titre in serum was still positive at 1:160, with mild clinical recovery. Clinical and laboratory follow up was maintained for 1 year, highlighting a fluctuating antibody titre related to both the clinical course and the immunosuppressive treatment.
The need of MOG-Ab laboratory follow-up is still debated, nevertheless it might be useful in predicting clinical relapse, as the presentation of this case report illustrates.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967